Capricor Therap (CAPR)
13.26  -1.08 (-7.53%)

Capricor Therapeutics is a clinical-stage biotechnology company focused on developing innovative cellular therapeutics to treat rare and chronic diseases. The company primarily works on harnessing the potential of stem cell-derived therapies, with a particular emphasis on cardiac and musculoskeletal conditions. Capricor aims to advance its proprietary technologies through rigorous research and development, striving to bring transformative treatment options to patients with unmet medical needs. By leveraging its expertise and pioneering spirit, Capricor seeks to make significant contributions to the field of regenerative medicine.

SummaryNewsPress ReleasesChartHistorical
MarketBeat Week in Review – 9/30 - 10/4
A strong jobs report and a temporary settlement of the port strike lifted stocks but inflation and earnings data could set investors up for more volatility
Via MarketBeat · October 5, 2024
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy
Via MarketBeat · September 30, 2024